Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
Date:8/2/2012

SAN DIEGO, Aug. 2, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the second quarter and six months ended June 30, 2012.

Net product revenue in the second quarter was $11.1 million, an increase of $3.1 million, or 38%, from the first quarter of 2012. This increase marks the company's sixth consecutive quarter of net product revenue growth since launching OFIRMEV® (acetaminophen) injection in January 2011.

A summary of the recent highlights and events for the company include the following:

  • Net product revenue of $11.1 million for the second quarter of 2012 and $19.1 million for the six months ended June 30, 2012
  • A 40% increase in the customer base for OFIRMEV in the first half of 2012 to nearly 3,200 unique customers at June 30, 2012
  • A New Drug Submission for OFIRMEV submitted to Health Canada in July 2012
  •  

    "OFIRMEV demand continues to accelerate, and exceeded our expectations in the second quarter of this year. I'm very pleased with how our sales team is executing on our strategy. Our customer base is growing rapidly, as physicians continue to embrace OFIRMEV as the foundation of a multi-modal approach to managing acute pain," said Ted Schroeder, President and CEO of Cadence. "Since launch, we believe that between 1.2 million and 1.5 million patients in the United States have been treated with OFIRMEV."

    Financial Results
    For the three months ended June 30, 2012, Cadence reported net product revenue of $11.1 million, an increase of $9.4 million from the $1.7 million of net product revenue reported for the three months ended June 30, 2011. For the six months ended June 30, 20
    '/>"/>

    SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
    2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
    3. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
    4. Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results
    5. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    6. Global Biopharmaceuticals Market 2011-2015
    7. Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
    8. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
    9. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
    10. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
    11. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biochips and Microarrays - ... This report is an analysis of ... report starts with a description of technologies as ... array comparative genomic hybridization (CGH), copy number variation ...
    (Date:9/2/2015)... Sep. 02, 2015 Research ... of Jain PharmaBiotech,s new report "Gene Therapy - ... The markets for gene therapy are difficult to ... product and it is marketed in China ... for the years 2014-2024. The estimates are based on ...
    (Date:9/2/2015)... ... September 02, 2015 , ... Drug companies increasingly are ... BCC Research reveals in its new report that the U.S. will generate the ... and generates the most market demand. , BCC Research examines plant-derived drugs ...
    (Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, ... developing treatments for urological and related conditions, announced today ... planned private placement convertible note financing, raising a total ... tranches totaling $3.175 million. Josh ... from this private placement are intended to be used ...
    Breaking Biology Technology:Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
    ... RNA later is a tissue storage , ... tissues. (Ambion's new RNA later -ICE is designed ... with frozen tissues - see "<A , ... Grinding Frozen Tissue " for more information.) Tissue , ...
    ... , , NAVIGATE THIS ARTICLE: <A , ... <A , href="#3">RNA , ... Transfer > <A , href="#5">Hybridization, , ... href="#6">Stripping , & Reprobing , , ...
    ... RNA is often labeled with fluorescent , ... may be , directly incorporated during ... post-aRNA reverse transcription (RT) reaction, or attached via a , ... (post-synthesis). Direct labeling requires the enzymatic , ...
    Cached Biology Technology:RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 2RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 3RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 4RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 5RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 6RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 7Northern Analysis: The Basics 2Northern Analysis: The Basics 3Northern Analysis: The Basics 4Northern Analysis: The Basics 5Northern Analysis: The Basics 6Northern Analysis: The Basics 7Northern Analysis: The Basics 8Northern Analysis: The Basics 9Northern Analysis: The Basics 10Northern Analysis: The Basics 11Northern Analysis: The Basics 12Northern Analysis: The Basics 13Northern Analysis: The Basics 14Northern Analysis: The Basics 15Northern Analysis: The Basics 16Northern Analysis: The Basics 17Northern Analysis: The Basics 18Northern Analysis: The Basics 19Amino Allyl Labeling for Array Analysis 2
    (Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
    (Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
    (Date:8/5/2015)... York , August 5, 2015 ... report titled "Facial Recognition Market - Global Industry Analysis, ... the global market for facial recognition is forecast to ... driven by increased demand for surveillance systems by civil ... rising number of crimes and terrorist activities across the ...
    Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
    ... of double-amputee Olympic hopeful Oscar Pistorius give him a clear ... more off what his 400-meter race time would be if ... released to the public for the first time ... in Dallas and Matthew Bundle of the University of Wyoming. ...
    ... much bigger animals, despite only having a brain the ... University of London. "Animals with bigger brains are ... of Sensory and Behavioural Ecology at Queen Mary,s Research ... Niven. This begs the important question: what are they ...
    ... regimens and the best efforts of nurses and doctors, about ... infections. But a revolutionary new wound dressing developed at Tel ... Meital Zilberman of TAU,s Department of Biomedical Engineering has developed ... fibers that can be loaded with drugs like antibiotics to ...
    Cached Biology News:Oscar Pistorius' artificial limbs give him clear, major advantage for sprint running 2Oscar Pistorius' artificial limbs give him clear, major advantage for sprint running 3Bigger not necessarily better, when it comes to brains 2A second skin 2
    Non-Protein Peroxidase Stabilizer , 1 L...
    Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
    RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
    Request Info...
    Biology Products: